124 related articles for article (PubMed ID: 38238117)
1. Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer.
Kohut-Jackson A; Orf J; Barresi D; Davaro F; Hamilton Z
Urol Oncol; 2024 May; 42(5):160.e25-160.e31. PubMed ID: 38238117
[TBL] [Abstract][Full Text] [Related]
2. Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Krabbe LM; Westerman ME; Margulis V; Raj GV; Sagalowsky AI; Courtney K; Arriaga Y; Lotan Y
Can J Urol; 2015 Aug; 22(4):7865-75. PubMed ID: 26267024
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
[TBL] [Abstract][Full Text] [Related]
5. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
6. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database.
Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG
Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
[TBL] [Abstract][Full Text] [Related]
8. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
9. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
Reardon ZD; Patel SG; Zaid HB; Stimson CJ; Resnick MJ; Keegan KA; Barocas DA; Chang SS; Cookson MS
Eur Urol; 2015 Jan; 67(1):165-170. PubMed ID: 24472710
[TBL] [Abstract][Full Text] [Related]
10. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
11. Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database.
Fu M; Klose C; Sparks A; Whalen M
Clin Genitourin Cancer; 2022 Apr; 20(2):e135-e139. PubMed ID: 34961704
[TBL] [Abstract][Full Text] [Related]
12. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
[No Abstract] [Full Text] [Related]
13. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database.
Zaid HB; Patel SG; Stimson CJ; Resnick MJ; Cookson MS; Barocas DA; Chang SS
Urology; 2014 Jan; 83(1):75-80. PubMed ID: 24231210
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
[TBL] [Abstract][Full Text] [Related]
15. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.
McFerrin C; Davaro F; May A; Raza S; Siddiqui S; Hamilton Z
Investig Clin Urol; 2020 Nov; 61(6):565-572. PubMed ID: 32985142
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
[TBL] [Abstract][Full Text] [Related]
17. Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
Grassauer J; Schmidt J; Cowan A; Gilbert SM; Chakiryan NH
Eur Urol Oncol; 2024 Feb; 7(1):139-146. PubMed ID: 37453853
[TBL] [Abstract][Full Text] [Related]
18. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
